Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
COMPARISON OF ACECLOFENAC WITH PIROXICAM IN THE TREATMENT OF OSTEOARTHRITIS
Autore:
BUSQUIER MP; CALERO E; RODRIGUEZ M; ARCE PC; BERMUDEZ A; LINARES LF; MESA J; CRISOSTOMOS CF; GARCIA C; LOPEZ AG; VALENZUELA A; POVEDANO A; PEREZ SG; LOPEZ MA; CALIZ R; VILLALBA FG; CANO M; MARTINEZ FG; GONZALEZ J; CARACUEL MA; ROLDAN R; UBEDA MG; GONZALEZ A; DELAFUENTE ILM; REJON E; SARABIA FN; PRIETO J; GONZALEZ J; RODRIGUEZ JM; DIAZ MR; MANZANO F; PEREZBENEGAS J; POU MA;
Indirizzi:
PRODESFARMA RES CTR,APARTADO POB 26 SANT JUST DESVERN 08960 BARCELONASPAIN HOSP CARLOS HAYA MALAGA SPAIN
Titolo Testata:
Clinical rheumatology
fascicolo: 2, volume: 16, anno: 1997,
pagine: 154 - 159
SICI:
0770-3198(1997)16:2<154:COAWPI>2.0.ZU;2-4
Fonte:
ISI
Lingua:
ENG
Soggetto:
NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ANTI-INFLAMMATORY DRUGS; OSTEO-ARTHRITIS; TOLERABILITY; NSAID;
Keywords:
ACECLOFENAC; NSAID; PIROXICAM; OSTEOARTHRITIS; EFFICACY; SAFETY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
25
Recensione:
Indirizzi per estratti:
Citazione:
M.P. Busquier et al., "COMPARISON OF ACECLOFENAC WITH PIROXICAM IN THE TREATMENT OF OSTEOARTHRITIS", Clinical rheumatology, 16(2), 1997, pp. 154-159

Abstract

A multicentre, double-blind, randomised, parallel group study was undertaken to investigate the efficacy and safety of aceclofenac (123 patients, 100 mg twice daily) in comparison to piroxicam (117 patients, 20 mg once daily and placebo once daily) in patients with osteoarthritis of the knee. The treatment period of two months was preceded by a washout period of one week duration. On completion of the study, patients in both aceclofenac and piroxicam-treated groups exhibited significant improvement in pain intensity and functional capacity of the affected knee, as represented by the Osteoarthritis Severity Index (OSI) (p<0.0001 and p<0.001 respectively). This was further substantiated following the patient's assessment of pain intensity using the Visual Analogue Scale (VAS), in which significant improvements were demonstrated at all time points for each treatment group (p<0.001). Although both treatment groups showed a significant improvement in all investigator's clinical assessments (functional exploration of the knee, knee flexionand extension (EXT)), there were no significant differences between the groups. There was, however, a more rapid improvement in knee flexion in the aceclofenac group after 15 days of treatment. Both aceclofenac and piroxicam were well tolerated by patients, the most commonly reported adverse events being gastrointestinal, although their incidence was low. Only 24 patients on aceclofenac, as opposed to 33 on piroxicam complained of dyspepsia, epigastralgia and pyrosis. While 7 patientsin each group were withdrawn because of adverse events, only one patient with piroxicam was withdrawn because of severe upper gastrointestinal bleeding. Twice as many reports of fecal blood loss were made in the piroxicam group in comparison to the aceclofenac group. In summary,this study confirms the therapeutic efficacy of aceclofenac and suggests that it is a well-tolerated alternative NSAID to piroxicam in the treatment of osteoarthritis.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/09/20 alle ore 15:59:29